# Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

> **NCT05545124** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Donafenib + Tislelizumab

## Key facts

- **NCT ID:** NCT05545124
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11
- **Primary completion:** 2023-11
- **Final completion:** 2024-11
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2022-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05545124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05545124, "Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05545124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*